{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:30:43Z","timestamp":1786681843623,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To evaluate the association of serum irisin, together with reproductive endocrine and metabolic indicators, with clinical pregnancy outcomes following\n                      <jats:italic>in vitro<\/jats:italic>\n                      fertilization and embryo transfer (IVF-ET) in women with polycystic ovary syndrome (PCOS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective cohort study included 92 infertile PCOS patients who underwent their first IVF-ET treatment at our hospital from February 2022 to February 2024. Available baseline data, IVF-related treatment parameters, reproductive endocrine and metabolic indicators were retrospectively collected from the medical records, and pregnancy outcomes were followed up. Univariate analysis and multivariate logistic regression models were used to evaluate independent factors affecting pregnancy outcomes. Receiver operating characteristic (ROC) curve analysis was conducted to assess the predictive value of related indicators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The pregnancy success group (n=44) was younger, required a lower total dose of gonadotropins (Gn), and retrieved more oocytes (P&amp;lt;0.05). Regarding reproductive endocrine parameters, the success group had higher levels of follicle-stimulating hormone (FSH), progesterone (P), and sex hormone-binding globulin (SHBG), and a lower luteinizing hormone (LH)\/FSH ratio (P&amp;lt;0.05). Metabolically, the success group showed significantly lower fasting blood glucose (FBG), fasting insulin (FINS), homeostasis model assessment of insulin resistance (HOMA-IR), triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C), but higher high-density lipoprotein cholesterol (HDL-C) levels compared with the failure group (P&amp;lt;0.001). Multivariate logistic regression indicated that LH\/FSH ratio (OR\u00a0=\u00a00.616), free testosterone index (FTI, OR\u00a0=\u00a00.363), irisin (OR\u00a0=\u00a00.401), and Gn dosage (OR\u00a0=\u00a00.445) were independent factors associated with lower odds of clinical pregnancy success (P&amp;lt;0.05). ROC curve analysis suggested that LH\/FSH ratio, free testosterone index (FTI), irisin, and Gn dosage had moderate predictive value for pregnancy outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The reproductive endocrine and metabolic characteristics of PCOS patients partially influence pregnancy outcomes following IVF-ET. Among the available endocrine, metabolic, and treatment-related indicators, LH\/FSH ratio, FTI, irisin, and Gn dosage may serve as reference indicators for predicting IVF-ET pregnancy outcomes, suggesting that a more favorable endocrine and metabolic profile may be related to improved clinical pregnancy probability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1894019","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:22:40Z","timestamp":1786681360000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Irisin and endocrine-metabolic indicators as predictors of IVF-ET pregnancy outcomes in Chinese women with PCOS"],"prefix":"10.3389","volume":"17","author":[{"given":"Huixia","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Fifth People\u2019s Hospital of Huai\u2019an","place":["Jiangsu, Huai\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlin","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Gynecological Endocrinology and Reproductive Medicine, Obstetrics and Gynecology Hospital Affiliated to Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Fifth People\u2019s Hospital of Huai\u2019an","place":["Jiangsu, Huai\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Fifth People\u2019s Hospital of Huai\u2019an","place":["Jiangsu, Huai\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Bi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Fifth People\u2019s Hospital of Huai\u2019an","place":["Jiangsu, Huai\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilin","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Fifth People\u2019s Hospital of Huai\u2019an","place":["Jiangsu, Huai\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Fifth People\u2019s Hospital of Huai\u2019an","place":["Jiangsu, Huai\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dey363","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"33","author":"Teede","year":"2018","journal-title":"Hum Reprod"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew218","article-title":"The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"31","author":"Bozdag","year":"2016","journal-title":"Hum Reprod"},{"key":"B3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1210\/er.2015-1104","article-title":"The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited","volume":"37","author":"Rosenfield","year":"2016","journal-title":"Endocr Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.24","article-title":"Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment","volume":"14","author":"Escobar-Morreale","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2021.02.023","article-title":"In vitro fertilization outcomes in women with polycystic ovary syndrome: a meta-analysis","volume":"259","author":"Tang","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmv029","article-title":"Pregnancy complications in women with polycystic ovary syndrome","volume":"21","author":"Palomba","year":"2015","journal-title":"Hum Reprod Update"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000004863","article-title":"Association between polycystic ovary syndrome and the risk of pregnancy complications: a PRISMA-compliant systematic review and meta-analysis","volume":"95","author":"Yu","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/humupd\/dmq032","article-title":"Extra-and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence","volume":"17","author":"Qiao","year":"2011","journal-title":"Hum Reprod Update"},{"key":"B9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12958-022-01035-9","article-title":"Association of ADAMTS proteoglycanases downregulation with IVF-ET outcomes in patients with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"20","author":"Shi","year":"2022","journal-title":"Reprod Biol Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1552561","article-title":"Embryological and pregnancy outcomes of IVF-ET in overweight\/obese and normal-weight women with PCOS","volume":"16","author":"Huang","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-01057-w","article-title":"Polycystic ovary syndrome as a metabolic disease","volume":"21","author":"Helvaci","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5250162","article-title":"Risk of type 2 diabetes mellitus following gestational diabetes pregnancy in women with polycystic ovary syndrome","volume":"2017","author":"Lo","year":"2017","journal-title":"J Diabetes Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.221","article-title":"Physiology and role of irisin in glucose homeostasis","volume":"13","author":"Perakakis","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123260","article-title":"The role of irisin throughout women's life span","volume":"11","author":"Barbagallo","year":"2023","journal-title":"Biomedicines"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3760\/cma.j.issn.0529-567x.2018.01.002","article-title":"Chinese guidelines for the diagnosis and treatment of polycystic ovary syndrome","volume":"53","year":"2018","journal-title":"Chin J Obstet Gynecol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-023-01055-z","article-title":"Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"21","author":"Greff","year":"2023","journal-title":"Reprod Biol Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"16057","DOI":"10.1097\/aog.0000000000002698","article-title":"Polycystic ovary syndrome","volume":"2","author":"Azziz","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B18","doi-asserted-by":"publisher","first-page":"8229","DOI":"10.1038\/s41598-024-58064-0","article-title":"Mechanism of elevated LH\/FSH ratio in lean PCOS revisited: a path analysis","volume":"14","author":"Pratama","year":"2024","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/rep-14-0517","article-title":"Role of androgens in normal and pathological ovarian function","volume":"149","author":"Walters","year":"2015","journal-title":"Reproduction"},{"key":"B20","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications","volume":"33","author":"Diamanti-Kandarakis","year":"2012","journal-title":"Endocr Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.coemr.2020.02.009","article-title":"Polycystic ovary syndrome and gestational weight gain","volume":"12","author":"Khomami","year":"2020","journal-title":"Curr Opin Endocr Metab Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2544","article-title":"Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome","volume":"100","author":"Li","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/biom14101222","article-title":"Irisin in reproduction: its roles and therapeutic potential in male and female fertility disorders","volume":"14","author":"Khan","year":"2024","journal-title":"Biomolecules"},{"key":"B24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13048-024-01372-w","article-title":"Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization\/intracytoplasmic sperm injection cycles: a systematic review with meta-analysis","volume":"17","author":"Palomba","year":"2024","journal-title":"J Ovarian Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.922044","article-title":"The essential role of body weight in adjusting Gn dosage to prevent high ovarian response for women with PCOS during IVF: a retrospective study","volume":"13","author":"Zeng","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12958-021-00802-4","article-title":"Research progress of endometrial receptivity in patients with polycystic ovary syndrome: a systematic review","volume":"19","author":"Bai","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/09513590903247873","article-title":"An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome","volume":"26","author":"Glintborg","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-92589-5_22","article-title":"Economic burden of polycystic ovary syndrome","volume-title":"Polycystic Ovary Syndrome: Current and Emerging Concepts","author":"Riestenberg","year":"2022"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/1179558119874042","article-title":"Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies","volume":"13","author":"Barber","year":"2019","journal-title":"Clin Med Insights Reprod Health"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25041976","article-title":"Current insights in prolactin signaling and ovulatory function","volume":"25","author":"Szukiewicz","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26094239","article-title":"Abnormally increased prolactin levels in women with polycystic ovarian syndrome are associated with risk of obesity, insulin resistance and prediabetes","volume":"26","author":"Yanachkova","year":"2025","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1894019\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:22:42Z","timestamp":1786681362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1894019\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":31,"alternative-id":["10.3389\/fendo.2026.1894019"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1894019","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1894019"}}